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Abstract
Evidence indicates that diets enriched in n-3 polyunsaturated fatty acids (n-3 PUFAs) reduce the risk of prostate can-
cer, but biochemical mechanisms are unclear. Syndecan-1 (SDC-1), a transmembrane heparan sulfate proteoglycan,
supports the integrity of the epithelial compartment. In tumor cells of epithelial lineage, SDC-1 is generally down-
regulated. This may result in perturbation of homeostasis and lead to progression of malignancy. Our studies have
shown that the n-3 PUFA species, docosahexaenoic acid (DHA), increases SDC-1 expression in prostate tissues of
Pten knockout (PtenP−/−) mice/cells and human prostate cancer cells. We have now determined that DHA-mediated
up-regulation of SDC-1 induces apoptosis. Bovine serum albumin–bound DHA and exogenous human recombinant
SDC-1 ecotodomain were delivered to PC3 and LNCaP cells in the presence or absence of SDC-1 small interfering
(si)RNA. In the presence of control siRNA, both DHAand SDC-1 ectodomain induced apoptosis,whereas SDC-1 silenc-
ing blocked DHA-induced but not SDC-1 ectodomain-induced apoptosis. Downstream effectors of SDC-1 signaling
linked to n-3 PUFA-induced apoptosis involved the 3′-phosphoinositide–dependent kinase 1 (PDK1)/Akt/Bad integrat-
ing network. A diet enriched in n-3 PUFA decreased phosphorylation of PDK1, Akt (T308), and Bad in prostates of
PtenP−/−mice. Similar results were observed in human prostate cancer cells in response to DHA and SDC-1 ectodo-
main. The effect of DHA on PDK1/Akt/Bad signaling was abrogated by SDC-1 siRNA. These findings define a mecha-
nism by which SDC-1–dependent suppression of phosphorylation of PDK1/Akt/Bad mediates n-3 PUFA-induced
apoptosis in prostate cancer.
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Introduction
Prostate cancer is the most frequently diagnosed cancer and a leading
cause of male cancer-related death in the United States. Epidemiological
studies that show geographical variations in prostate cancer incidence
and mortality [1,2] and migration-associated changes in risk [3,4] have
provided evidence that environmental and lifestyle-related factors,
including diet, may contribute to this disease. Of particular interest
are the long-chain marine n-3 polyunsaturated fatty acids (PUFAs),
eicosapentaenoic acid (EPA, [20:5, n-3]), and docosahexaenoic acid
(DHA, [22:6, n-3]), which are reported to be lower in plasma [5] and
prostate tissue [6,7] of prostate cancer patients compared with cancer-
free men. Moreover, cell culture and animal models have indicated that
higher levels of n-6 PUFA drive prostate cancer growth, whereas n-3
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PUFA are protective [8–10]. Although a number of biologic pathways
have been implicated in the cancer-promoting and cancer-protective
properties of n-6 PUFA and n-3 PUFA, respectively (reviewed in
Larsson et al. [11] and Berquin et al. [12]), the molecular mechanisms
remain poorly understood.
Syndecan-1 (SDC-1) is a transmembrane heparan sulfate proteoglycan
known to play a role in the regulation of cell-cell and cell-matrix inter-
actions, cell migration, adhesion, differentiation, and tumorigenesis
[13–18]. A biologically active ectodomain of SDC-1 can be shed from
the cell through the action of matrix-metalloproteinases [19–21]. Low
levels or a complete loss of SDC-1 in tumor cells is associated with
tumor progression and aggressive phenotypes of various cancers [22–
25], whereas re-expression of SDC-1 restores the epithelial morphology
and suppresses hormone-induced growth of tumor cells [26]. In human
prostate cancer, recent studies show that there is an inverse correlation
between SDC-1 expression and Gleason grade of prostate cancer
[27,28]. SDC-1 is uniformly expressed in the basolateral membrane of
normal epithelia, but its distribution shifts from the plasma membrane
to the cytoplasm in prostate cancer cells [27]. In contrast, enhanced
expression of SDC-1 also corresponds with unfavorable phenotypes in
some cancers including ovarian, breast, pancreatic, endometrial cancers,
and glioma [29–33]. Furthermore, mounting evidence implicates dis-
crepant effects of epithelial and stromal cell SDC-1 [24], but how
SDC-1 as a key regulator of epithelial-stromal interaction modifies the
tumor microenvironment and affects tumor progression is unknown.
In addition, SDC-1 extracellular domain shedding is believed to contrib-
ute to diverse pathophysiological events including cancer [34], although
the spatial regulation of SDC-1–extracellular matrix engagement through
shedding needs to be further investigated.
Our previous studies have shown that n-3 PUFAs increase SDC-1 ex-
pression in prostate cancer cells through a transcriptional pathway in-
volving peroxisome proliferator–activated receptor γ (PPARγ) [35]. In
the present study, we have used prostate-specific Pten (phosphatase and
tensin homolog deleted on chromosome 10) knockout mice and human
prostate cancer cells to explore functional outcomes of SDC-1 up-
regulation by n-3 PUFA. We found that n-3 PUFA regulated an SDC-
1–dependent pathway that involved inhibition of 3′-phosphoinositide–




Anti-Akt, anti–phospho-Akt (S473), anti–phospho-Akt (T308),
anti–phospho-PDK1 (S243), anti-PDK1, anti–phospho-Bad (S112),
anti-Bad, anti–poly(ADP-ribose) polymerase (PARP), and anti–HRP-
conjugated secondary antibody against rabbit were purchased from Cell
Signaling Technology (Danvers, MA). Anti–SDC-1 (H-174) antibody
and normal rabbit lgG were from Santa Cruz Biotechnology, Inc
(Santa Cruz, CA). CellTiter 96 Aqueous One Solution Cell Prolifera-
tion Assay and Caspase-Glo 3/7 Assay were from Promega (Madison,
WI). Wortmannin was purchased from Sigma-Aldrich Company Ltd
(Allentown, PA). Hoechst 33342 was from Invitrogen (Eugene, OR).
EPA and DHA were from Sigma Chemical Co (St Louis, MO) and
prepared as 600-μM stocks complexed to bovine serum albumin
(BSA) as described [36]. Low-density lipoproteins (LDLs) were isolated
from plasma of adult vervet monkeys fed n-3 PUFA (fish oil)–enriched
diets for more than 3 years. LDL isolation and characterization pro-
cedures were previously described [36].
Cell Lines and Cell Culture
PC3, LNCaP, and DU145 cells were purchased from the American
Type Culture Collection (Manassas, VA) and maintained in advanced
Dulbecco’s modified Eagle medium (Invitrogen, Grand Island, NY)
containing 1% fetal bovine serum (FBS; PC3 cells), RPMI 1640
medium (Invitrogen) with 10% FBS (LNCaP cells), or Eagle minimum
essential medium with Earl’s salts medium (Invitrogen) containing
10%FBS (DU145 cells). Normal human prostate epithelial cells (PrEC)
were purchased from Clonetics (San Diego, CA) and were maintained
in Clonetics Prostate Epithelial Cell Medium. Mouse prostate epithe-
lial cells derived from PtenP+/+ and PtenP−/− mice were provided by
Dr. Scott D. Cramer (Wake Forest University School of Medicine)
and maintained in advanced Dulbecco’s modified Eagle medium con-
taining 1% FBS. Cell Pten status was confirmed by Western analysis.
Mice
As previously described [10,37,38], prostate-specific Pten-knockout
mice were generated by crossing Pten loxP/loxP mice with mice of
the ARR2Probasin-cre transgenic line PB-cre4, wherein the Cre re-
combinase is under the control of a modified rat prostate-specific pro-
basin promoter. For simplicity, PtenloxP/loxPPB-cre4−/− and PtenloxP/
+PB-cre4−/− are referred to as PtenP+/+ and PtenloxP/loxP PB-cre4T/− as
PtenP−/−. PtenP+/+ and PtenP−/−mice were used in this study. Mice were
fed a high n-3 (n-6: n-3 ratio = 1:1) or a high n-6 (n-6: n-3 ratio =
40:1) diet for 8 weeks. Diet composition, body weights, fatty acid ratios
in food, blood, and prostate tissues and dissection of prostate lobes have
been described [10]. Animal care was conducted in compliance with
the state and federal Animal Welfare Acts and standards and policies
of the Department of Health and Human Services. The protocol was
approved by our Institutional Animal Care and Use Committee.
Preparation of Recombinant SDC-1 Ectodomain
The preparation of SDC-1 ectodomain was previously described
[39]. Briefly, SDC-1 ectodomain expression construct was designed
to encode a COOH-terminal polyhistidine fusion protein and was
created using a two-step cloning process as follows. The SDC-1 ecto-
domain complementary DNA (cDNA) was amplified by polymerase
chain reaction (PCR) using the SDC-1 plasmid (OriGene Technolo-
gies, Inc, Rockville, MD). The resulting cDNA was cut with BamHI
and EcoRI restriction endonucleases and ligated into the pTcam4 ex-
pression plasmid. In the second round of PCR, 5′-gcaaagcttgaattcggca-
gcatgaggcgcgcg-3′ (forward) and 5′-gcaaagcttgaattcggcagcatgaggcgcgcg-
3′ (reverse) primers were used to amplify the SDC-1 ectodomain cDNA.
The amplified cDNA was treated with HindIII and XhoI and sub-
sequently ligated into the pCEP4 (Invitrogen) expression plasmid, then
transfected into 293-EBNA cells. The stable expressing cells selected
by the addition of 200 μg/ml hygromycin B were cultured, and the con-
ditioned medium was used to purify recombinant SDC-1 ectodomain
by Millipore Pellicon 2 tangential flow system (Millipore Corp, Billerica,
MA) and anion exchange chromatography.
Cell Growth Assay
Prostate cancer cells were plated in 96-well plates at a density of 2 ×
103 cells per well in 100 μl of medium. After treatment with DHA
or SDC-1 ectodomain, cell growth was measured using a CellTiter
96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega) based
on the manufacturer’s protocol. Data represent the mean absorbance
of three wells, and these are presented relative to control.
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Western Blot Assay
Mouse prostate tissues were homogenized and lysed in ice-cold
lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100,
0.1 mg/ml phenylmethanesulfonyl fluoride) with 1× proteinase and 1×
phosphatase inhibitors (Roche Applied Science, Indianapolis, IN). Ly-
sates of human prostate cancer cells were similarly prepared. For the
analysis of SDC-1 protein, lysates were dialyzed against 100 mM Tris
and 30 mM sodium acetate, pH 8.0 for 24 hours at 4°C, and then
digested by chondroitinase ABC (Seikagaku, Ijamsville, MD) and hep-
arinase III (Sigma-Aldrich) at 37°C overnight. Protein extracts were
prepared for Western blot analysis as described earlier using indicated
antibodies [40]. Band densities on photographic films were analyzed
using Image J 1.37v (National Institutes of Health, Bethesda, MD).
SDC-1 Gene Silencing by Small Interfering RNA
Two SDC-1 small interfering RNA (siRNA) specific for human
SDC-1 gene were purchased from Ambion (catalog no. AM16708A
[SDC-1 siRNA I] and catalog no. AM16708 [SDC-1 siRNA III];
Austin, TX). Cells were plated in six-well plates at a density of 2.0 ×
105 cells per well, and transfected with siRNA using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol. Control
cells received a negative control siRNA with no known target. At
6 hours after transfection, wells were supplemented with medium con-
taining 1% FBS for 24 hours. The most effective siRNA (AM16708A,
SDC-1 siRNA I) in silencing SDC-1 gene expression was used for
further experiments.
Quantitative Real-time PCR
Quantitative real-time PCR (RT-PCR) was performed as described
[39,41]. Briefly, total cell RNA was prepared. Amplification reactions
were performed in triplicate in Applied Biosystems 7500 Real-Time
PCR System. The primers used for mouse SDC-1 were 5′-tggagaacaaga-
cttcacctttg-3′ (forward) and 5′-ctcccagcacttccttcct-3′ (reverse), and those
for human SDC-1 were 5′-ggagcaggacttcacctttg (forward) and 5′-
ctcccagcacctctttcct (reverse). Primers for mouse peptidylprolylisomerase
B housekeeping gene were 5′-gcccaaagtcaccgtcaa (forward) and 5′-
tccgaagagaccaaagatcac (reverse), and those for human were 5′-gcccaaa-
gtcaccgtcaa (forward) and 5′-tccgaagagaccaaagatcac (reverse). Data were
Figure 1. Effects of n-3 PUFA on apoptosis in human prostate cancer cells. (A) PC3 cells were treated with n-3 PUFA–enriched LDL (100 μg/
ml), DHA-BSA, or EPA-BSA (30 μM) for 48 hours. Protein extracts were used for Western blot analysis of cleaved PARP and β-actin. Values
representing the cleaved PARP/β-actin mean ratios compared with controls (n = 3) with different letters are significantly different (P <
.05). (B) PC3 and LNCaP cells were treated with n-3 and n-6 PUFA–enriched LDL (100 μg/ml), DHA-BSA, or EPA-BSA (30 μM) for 48 hours.
Caspase 3 activity was measured with the Caspase-Glo 3/7 assay. Values representing the mean ± SD (n = 3) with different letters are
significantly different (P < .05). (C) PC3 cells were treated with indicated concentrations of DHA-BSA or EPA-BSA for indicated times.
Caspase 3 activity was measured with the Caspase-Glo 3/7 assay. Values representing the mean ± SD (n = 3) with different letters are
significantly different (P < .05). (D) PC3, LNCaP, and DU145 cells were treated with DHA-BSA (30 μM) for 48 hours. Caspase 3 activity
was measured with the Caspase-Glo 3/7 assay. Values representing the mean ± SD (n = 3) with different letters are significantly different
(P < .05). (E) PC3 and LNCaP cells were treated with indicated concentrations of DHA-BSA. Cell growth was measured using MTS assay
and compared with that of controls (untreated cells) at the same time point. Means ± SD (n = 3) are presented.
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normalized to the housekeeping control peptidylprolylisomerase B, and
these are presented relative to control.
Detection of Apoptosis
PC3 and/or LNCaP cells transfected with SDC-1 siRNA or control
siRNA were treated with DHA or SDC-1 ectodomain. Apoptosis was
measured by cleaved PARP using Western blot assay or caspase 3 activ-
ity using Caspase-Glo 3/7 assay following the manufacturer’s protocol
and/or Hoechst 33342 staining.
Statistical Analysis
Data are expressed as mean and SD or SE. Statistical analysis was
performed using one-way analysis of variance. P < .05 was considered
statistically significant.
Results
Apoptosis Is Induced by n-3 PUFA in Human Prostate
Cancer Cells
Our previous studies had shown that LDL isolated from monkeys
fed an n-3 PUFA-enriched diet contained two major species of n-3
PUFA, namely, EPA and DHA, and both were effectively delivered
to the cells by the LDL [35,36]. To determine the effects of the indi-
vidual n-3 PUFA in apoptosis induction, PC3 cells were incubated with
the n-3 PUFA-enriched LDL, BSA-bound DHA, or BSA-bound EPA
for 48 hours, and apoptosis was measured by PARP cleavage. The n-3
LDL and DHA significantly increased cleaved PARP levels compared
with control cells, whereas EPA was ineffective (Figure 1A). Apoptosis
was confirmed in PC3 and LNCaP treated with n-3 LDL and DHA
by Caspase-Glo 3/7 Assay (Figure 1, B and C). As shown in Figure 1C ,
apoptosis induction by DHAwas dose-dependent, whereas no apopto-
tic effect was observed with BSA-bound EPA and n-6 PUFA-enriched
LDL at similar doses in cells treated for up to 72 hours (Figure 1, A-C).
In addition, DU145 cells were slightly less sensitive to DHA-induced
apoptosis than PC3 and LNCaP cells (Figure 1D). Consistent with the
induced apoptosis, DHA inhibited cell growth in a dose- and time-
dependent manner in PC3 and LNCaP cells (Figure 1E).
SDC-1 Is Upregulated by n-3 PUFA In Vivo and In Vitro
Our previous studies have identified SDC-1 expression in prostate
tissue of C57BL/6J mouse and in human prostate cancer cells. SDC-1
gene expression was increased when mice were fed an n-3 PUFA–
enriched diet or when cells were treated with n-3 LDL or BSA-bound
DHA [35]. In the present study, Pten deletion (PtenP−/−) and wild-type
(PtenP+/+) mice were used to further test the effect of n-3 PUFA on
SDC-1 protein expression. The PtenP−/− genotype develop hyperplasia
at 4 weeks and progress through carcinoma in situ to invasive adenocar-
cinoma by 16 weeks. Mice were fed an n-3 PUFA– and n-6 PUFA–
enriched diet and killed at 8 weeks. Prostate lobes were dissected and
homogenized, and lysates were prepared for measurement of SDC-1
protein by Western blot analysis. SDC-1 level was lower in PtenP−/−
compared with PtenP+/+ mice (Figure 2A).Whereas the SDC-1 levels were
similar in PtenP+/+ mice fed n-3 PUFA or n-6 PUFA diets, SDC-1 pro-
tein was significantly elevated in PtenP−/− mice fed an n-3 PUFA diet
compared with those fed an n-6 PUFA diet. Cultured cells were derived
from the prostate tissue of the two mouse genotypes. Consistent with
data from the mouse tissues, expression of SDC-1 was markedly lower
Figure 2. SDC-1 up-regulation by n-3 PUFA in prostates of PtenP−/− mice/cells and in human prostate cancer cells. (A) Protein extracts
from the prostates of 8-week-old PtenP+/+ and PtenP−/− mice fed n-3 PUFA or n-6 PUFA diets were dialyzed and treated with heparinase
III plus chondroitin ABC lyase for 18 hours at 37°C. SDC-1 was measured byWestern blot assay and normalized to β-actin. Values represent-
ing themean and SD (n= 3) for SDC-1/β-actin ratios with different letters are significantly different (P< .05). (B) Cultured prostate cells from
PtenP+/+ and PtenP−/− mice were harvested at approximately 70% confluence, and (C) PtenP−/− prostate cells were incubated with n-3 or
n-6 PUFA-enriched LDL (100 μg/ml) for 8 hours. Total RNA was isolated, and SDC-1 mRNA was determined by real-time PCR. Values
expressed relative to controls (n = 3) with different letters are significantly different (P < .05). (D) Human prostate cells (normal prostate
epithelial cells [PrEC] and prostate cancer cells [PC3, LNCaP, and DU145]) were harvested at approximately 70% confluence. Total RNA
was isolated, and SDC-1 mRNA was determined by real-time PCR. Values, expressed relative to controls (n = 3), with different letters are
significantly different (P < .05).
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in PtenP−/− compared with PtenP+/+ cells (Figure 2B), and expression
of SDC-1 in PtenP−/− cells was increased by n-3 PUFA-enriched LDL
(Figure 2C). In addition, we demonstrated that endogenous SDC-1 ex-
pression was lower in three human prostate cancer cell lines compared
with nontumorigenic prostate epithelial cells (Figure 2D). It is of inter-
est to note that, as in the mouse PtenP−/− cells, SDC-1 expression was
lower in the two human Pten-negative cell lines, PC3 and LNCaP,
than in Pten-positive DU145 and PrEC cells (Figure 2D).
Apoptosis Is Induced by Exogenous SDC-1 Ectodomain in
Human Prostate Cancer Cells
Given that human prostate cancer cells had lower expression of
SDC-1 (Figure 2D), the consequence of providing the cells with exog-
enous SDC-1 was evaluated by measurement of apoptosis. PC3 and
LNCaP cells were incubated for 48 hours with two similar preparations
of SDC-1 ectodomain (Ect 1 and Ect 2) and a truncated ectodomain
(Mini) of human recombinant SDC-1. Ect 1 and Ect 2 significantly
increased caspase 3 activities in a dose-dependent manner in both cell
lines, whereas Mini had little ability to induce caspase 3 activation (Fig-
ure 3, A and B). Hoechst staining demonstrated that PC3 cells treated
with SDC-1 ectodomain (Ect 2) exhibited typical apoptotic nuclear
morphology characterized by chromatin condensation and DNA frag-
mentation (Figure 3C , upper). The quantitative analysis for apoptotic
cells confirmed that the cellular apoptosis elicited by SDC-1 ectodomain
was concentration-dependent, resulting in up to 20% apoptotic cells at
150 nM SDC-1 (Figure 3C , lower). Furthermore, the effect of SDC-1
ectodomains on apoptosis was blocked by an SDC-1 antibody but not
by a control IgG (Figure 3D). Consistent with apoptosis induction,
SDC-1 ectodomain (Ect 1) treatment led to a dose- and time-dependent
decrease in cell number of PC3 and LNCaP cells (Figure 3E).
Figure 3. SDC-1 ectodomain induces apoptosis in human prostate cancer cells. PC3 (A) and LNCaP (B) were treated with 50, 100, and
150 nM SDC-1 mini or ectodomain (Ect) preparations 1 or 2 for 48 hours. Caspase 3 activity was measured with the Caspase-Glo 3/7 assay.
Values expressed relative to controls (n = 3) with different letters are significantly different (P< .05). (C) PC3 cells were treated with SDC-1
Ect (50, 100, and 150 nM) for 48 hours. Cell morphologic changes were examined by Hoechst 33342 staining and observed by fluores-
cence microscopy at a magnification of ×40. Representative photographs were obtained from three separate experiments, in which
apoptotic cells with condensed nuclei and fragmented chromatin are indicated by insets with high-magnification images of the areas
in the white rectangles exposed to 100 and 150 nM SDC-1, respectively. The percentages of apoptotic cells are expressed in the graph
as means ± SD of three individual experiments. Values with different letters are significantly different (P < .05). (D) PC3 and LNCaP cells
were treated with SDC-1 Ect (150 nM) and SDC-1 antibody (SDC-1 Ab, 5 nM) or nonspecific lgG (5 nM) as a negative control for 48 hours.
Caspase 3 activity was measured with the Caspase-Glo 3/7 assay. Values expressed relative to controls (n = 3) with different letters are
significantly different (P < .05). (E) PC3 and LNCaP cells were treated with indicated concentrations of SDC-1 Ect. Cell growth was mea-
sured using MTS assay and compared with that of controls (untreated cells) at the same time point. Means ± SD (n = 3) are presented.
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Apoptosis Induction by n-3 PUFA Is SDC-1–Dependent
To test whether SDC-1 is a mediator in n-3 PUFA-induced apop-
tosis, two SDC-1 siRNA (SDC-1 siRNA I and SDC-1 siRNA III) were
transfected into PC3 and LNCaP cells. Both effectively inhibited
SDC-1 messenger RNA (mRNA) more than 90% for up to 72 hours
after transfection in PC3 cells (Figure 4A). Similar data were obtained
with LNCaP cells (not shown). On the basis of these effects, SDC-1
siRNA Iwas used for further experiments. Cells transfected for 24 hours
with either control siRNA (no known target) or SDC-1 siRNA were
exposed to 30 μMDHA for 48 hours, and caspase 3 activity was mea-
sured. As shown in Figure 4B, both DHA and SDC-1 ectodomain
significantly increased caspase activity in nontransfected and control
siRNA-transfected cells. However, SDC-1 siRNA effectively blocked
the ability of DHA to increase caspase 3 activity in both PC3 and LNCaP
cells. Caspase 3 induction by SDC-1 ectodomain was not blocked by
SDC-1 siRNA in either cell line. These data imply that DHA induces
apoptosis through an SDC-1–dependent mechanism.
Suppression of PDK1/Akt Activation by n-3 PUFA Is
Regulated by SDC-1
Akt is a critical survival kinase that controls programmed cell death.
Full activation of Akt requires phosphorylation on two highly con-
served residues, T308 and S473 [42]. T308 is phosphorylated by
protein serine/threonine kinase PDK1, whereas S473 is primarily phos-
phorylated by the mammalian target of rapamycin [43,44]. Phosphory-
lation on T308 is essential for Akt kinase activity [45]. To investigate
possible downstream signaling related to n-3 PUFA-induced apoptosis,
Akt and PDK1 status were examined byWestern blot assay in prostates
of PtenP+/+ and PtenP−/− mice fed an n-3 and n-6 PUFA–enriched diet.
No difference in phosphorylation of either Akt or PDK1 (ratios of
p-Akt [T308 or S473]/total Akt and p-PDK1/PDK1) was detected
between PtenP+/+ mice fed an n-3 and an n-6 PUFA diet (Figure 5A).
There was also no change in phosphorylation of Akt at S473 in prostates
of PtenP−/− mice fed an n-3 PUFA diet (Figure 5A), which is consistent
with our previous report [10]. However, we previously found an in-
crease in apoptosis [10], and here we show a significant decrease in phos-
phorylation of Akt at T308 and reduced phosphorylation of PDK1 in
prostates of PtenP−/− mice fed an n-3 PUFA–enriched diet (Figure 5A).
Similar results were observed in PC3 cells in response to DHA and
human SDC-1 ectodomain (Figure 5B). The effect of DHA on phos-
phorylation of Akt at T308 and phosphorylation of PDK1 was ab-
rogated by SDC-1 siRNA (Figure 6, A and B). In addition, SDC-1
knockdown led to activation of Akt at T308 in either PC3 or DU145
cells (Figure 6, B and C ). An Akt inhibitor, wortmannin, increased
caspase 3 activity to a similar extent as DHA (Figure 6D). LY294002,
another Akt inhibitor, also demonstrated a dose-dependent induction
of apoptosis in all three cell lines (not shown). These data show that
Figure 4. SDC-1 knockdown blocks DHA-induced apoptosis in human prostate cancer cells. (A) PC3 cells were transfected with a control
siRNA or two SDC-1 siRNA (I and III). At the indicated times after transfection, total RNA was isolated, and SDC-1 mRNA was determined
by real-time PCR. Both SDC-1 siRNA had similar effects on SDC-1 gene expression. Data shown are the levels of SDC-1 gene expression
relative to control (n = 3). Values representing the mean ± SD (n = 3) with different letters are significantly different (P < .05). (B) PC3 and
LNCaP cells were transfected with control siRNA or SDC-1 siRNA (I) for 6 hours, then supplemented with growth medium containing 1%
FBS for 24 hours. Cells were treated with DHA-BSA (30 μM) or SDC-1 ectodomain (100 nM) for 48 hours. Caspase 3 activity was measured
with the Caspase-Glo 3/7 assay. Values representing the mean ± SD (n = 3) with different letters are significantly different (P < .05).
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n-3 PUFA up-regulation of SDC-1 results in the suppression of phos-
phorylation of PDK1 and Akt followed by an induction of apoptosis.
Phosphorylation of Bad Is Inhibited by DHA through SDC-1
Bad plays an important role in mediating the apoptotic signal in
cells. Phosphorylation of Bad is necessary to protect prostate cancer cells
from apoptosis [46]. Our previous studies showed lower levels of phos-
phorylated Bad in prostate tumors of mice fed an n-3 PUFA–enriched
diet, and Bad knockdown in vitro eliminated the ability of n-3 PUFA
to induce cell death [10]. In this study, the involvement of SDC-1 in
the suppression of Bad phosphorylation by DHA was investigated in
PC3 and LNCaP cells. As shown in Figure 7, A and C , human
SDC-1 ectodomain and DHA decreased phosphorylation of Bad in a
dose-dependent manner in both cell lines. In addition, when a SDC-1
siRNA was transfected into cells to silence SDC-1 expression, inhibi-
tion of Bad phosphorylation by DHAwas blocked (Figure 7, B andD),
thus suggesting a modulating role of SDC-1 in DHA inhibition of
Bad phosphorylation.
Discussion
Apoptosis represents an effective way to eliminate cancer cells. Unfor-
tunately, advanced prostate tumors eventually progress to develop re-
sistance to current apoptosis-mediated therapeutic approaches [47].
However, increasing evidence from epidemiological, animal, and in vitro
studies indicates that n-3 PUFAs inhibit the promotion and progression
of prostate cancer. In the present studies, we have demonstrated that
n-3 PUFAs induce apoptosis and present the novel finding that apop-
tosis induction by the n-3 PUFA, DHA, is dependent on its ability
to increase the expression of the proteoglycan, SDC-1. In addition,
we have shown that the PDK1/Akt/Bad signaling pathway is affected
by SDC-1 to result in apoptosis induction. This finding may pave the
way for a newmechanism-based chemoprevention of n-3 PUFA in pros-
tate cancer.
SDC-1, a multifunctional proteoglycan, plays a key role in support
of homeostasis of the epithelial compartment of normal prostate and
nonmalignant hormone-responsive and well-differentiated prostate tu-
mors [48]. Therefore, alteration in SDC-1 content or structure may
disrupt homeostasis. Our studies show that basal SDC-1 expression
was lower in human prostate cancer cells and mouse Pten knockout
cells when compared with human normal prostate epithelial cells and
mouse Pten wild-type cells, respectively. Moreover, similar to the mouse
cells, SDC-1 expression was lower in the human Pten-null cell lines than
in the Pten-positive ones. The n-3 PUFA, DHA, stimulated SDC-1
expression in both mouse and human Pten-null cells. Because recom-
binant SDC-1 ectodomain was effective in inducing apoptosis and
concomitantly inhibiting the growth of the prostate cancer cells, resto-
ration of SDC-1 by DHA could be an effective way to restore a lost
homeostatic mechanism and thereby to impede the progression of pros-
tate cancer.
Epidemiological studies suggest that increased intake of n-3 PUFA-
rich fish or fish oil reduces prostate cancer progression, recurrence, and
mortality [49–52]. Serum levels of n-3 PUFA were reported to be sig-
nificantly lower in patients with benign prostate hyperplasia and pros-
tate cancer, and n-6 PUFA levels were higher in patients with prostate
cancer [5]. In prostate tissues, the percentage of total PUFA was shown
to be significantly lower in the presence of perineural invasion, seminal
vesicle involvement, and stage T3 tumor [53]. In addition, increased
levels of n-6 PUFA and the ratio of n-6/n-3 PUFAwere associated with
an increased mean prostate-specific antigen level and risk of prostate
cancer [54]. Recently, we have shown that n-3 PUFA–enriched diets
inhibit tumor growth and increase survival in Pten knockout mice, which
Figure 5. SDC-1 and n-3 PUFA reduce PDK-1 and Akt phosphorylation in vivo and in vitro. (A) Protein extracts from the prostates of 8-week-
old PtenP+/+ and PtenP−/− mice fed n-3 PUFA– and n-6 PUFA–enriched diets were used for Western blot analysis of p-PDK1(S243), PDK1,
p-Akt (S473 and T308), total Akt, and β-actin. The mean ± SD for ratios of P-PDK1 to PDK1 and p-Akt (S473 and T308) to Akt are shown in
the bottom graph. (B) PC3 cells were treated with SDC-1 ectodomain (50, 100, and 150 nM) and DHA-BSA (30 and 60 μM) for 48 hours.
Protein extracts were used for Western blot analysis of p-PDK1, PDK1, p-Akt (S473 and T308), total Akt, and β-actin.
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develop prostate cancer with 100% penetration, whereas an n-6 PUFA–
enriched diet had the opposite effect [10]. Our present studies in vitro
further show that at concentrations slightly lower than those found in
fasted human plasma, n-3 PUFA–enriched LDL induced apoptosis
and inhibited the growth of both androgen-dependent and androgen-
independent human prostate cancer cells. This suggests that increasing
the ambient n-3 PUFA in prostate tissue could retard progression to
androgen-independent growth. Analysis of the role of the two major ma-
rine n-3 PUFA species EPA and DHA found that DHA but not EPA
was effective in the induction of apoptosis. This is consistent with our
earlier study showing that DHA but not EPA upregulated SDC-1 ex-
pression in human prostate cancer cells [35]. Furthermore, SDC-1
knockdown by specific SDC-1 siRNA blocked the stimulatory effect
of DHA on apoptosis. These data strongly support a critical role of
SDC-1 in DHA-induced apoptosis in prostate cancer cells.
SDC-1 as a heparan sulfate–containing cell surface molecule can
simultaneously bind various components of the extracellular matrix and
members of the heparin-binding growth factors. Therefore, SDC-1 may
act as a coreceptor for growth factors, which could promote or restrict
their interaction with growth factor receptors [55–57]. In addition,
SDC-1 can be shed from the surface of cancer cells as an intact ecto-
domain, and this shed SDC-1 serves multiple functions including an
induction of apoptosis and inhibition of cell growth in vitro [34,58]. In
our study, we found that human normal prostate epithelial cells had
higher SDC-1 gene expression than human prostate tumor cells, but
comparing those tumor cells, the more aggressive cell line, DU145,
had higher basal level of SDC-1 than LNCaP cells. Considering that
SDC-1 up-regulation by DHA induces apoptosis, endogenously pro-
duced SDC-1 could be modulated by other factors or may need to be
shed to exert its apoptotic activity. Different biologic functions of shed
and membrane-bound SDC-1 have been reported in other systems
[34]. Further experiments are needed to clarify the complexity of bio-
logic consequences from endogenous and shed SDC-1 in the prostate
cancer cells.
Akt is a mediator of growth factor–induced survival and has the capac-
ity to drive tumor cell growth, proliferation, metabolism, and survival
Figure 6. SDC-1 knockdown blocks the effect of DHA on phosphorylations of PDK1/Akt, and an Akt inhibitor, wortmannin, induces apop-
tosis. (A and B) PC3 cells were transfected with control siRNA or SDC-1 siRNA for 6 hours then supplemented with growth medium contain-
ing 1% FBS for 24 hours. Cells were treated with DHA (60 μM) or SDC-1 ectodomain (150 nM) for 48 hours before harvest. PDK1, p-PDK1
(S243) (A), total Akt, and p-Akt (T308 and S473) (B) were measured by Western blot assay. All data shown are representative of three in-
dependent experiments. Relative ratios and SEM are shown in graph B. Values with different letters are significantly different (P < .05).
(C) DU145 cells were transfected with control siRNA or SDC-1 siRNA for 6 hours and then supplemented with growth medium containing
1% FBS for 24 hours. Cells were treated with DHA (60 μM) for 48 hours before harvest. Total Akt and p-Akt (T308 and S473) were mea-
sured by Western blot assay. All data shown are representative of three independent experiments. Relative ratios and SEM are shown.
Values with different letters are significantly different (P < .05). (D) PC3, LNCaP, and DU145 cells were treated with an Akt inhibitor,
wortmannin, at the indicated concentration for 48 hours. Caspase 3 activity was measured with the Caspase-Glo 3/7 assay. Values repre-
senting the mean ± SD (n = 3) with different letters are significantly different (P < .05).
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[59]. The most important upstream activators of Akt are the class I
phosphoinositide 3-kinases (PI3K) [42]. The membrane-associated
PI3K lipid products bind directly to the plekstrin homology domain of
Akt, resulting in its recruitment to the membrane, exposure of its two
main phosphorylation sites, and activation on T308 through PDK1,
which also has a plekstrin homology domain directing it to membrane
PI3K products, and on S473 through primarily mammalian target of
rapamycin [45,60]. Our data here show that n-3 PUFA and DHA
significantly inhibited phosphorylation of Akt at the T308 site, which
was also reflected in a decrease in phosphorylation of PDK1. Exoge-
nous SDC-1 mimicked the effect of DHA on Akt and PDK1 phos-
phorylation. Abrogation of SDC-1 expression by siRNA abolished the
inhibitory effect of DHA. Further, Bad protein is a switch integrating
the antiapoptotic effects of multiple pathways that suppress apoptosis
in Pten-deficient tumor cells [61]. PI3K/Akt mediates phosphorylation
of Bad to suppress cell death and promote cell survival [62]. In the pres-
ent study, we show that exogenous SDC-1 ectodomain and DHA inhib-
ited Bad phosphorylation in a dose-dependent manner in PC3 and
LNCaP cells. SDC-1 knockdown by siRNA completely eliminated the
effect of DHA but not of SDC-1 ectodomain. These results indicate
that the suppression of phosphorylation of Bad may involve SDC-1 to
promote the apoptotic effect of n-3 PUFA.
Taken together, these studies show that a novel mode of action by
which n-3 PUFA induces apoptosis in prostate cancer cells is through
up-regulating SDC-1 expression followed by concomitant suppressions
of PDK1/Akt/Bad phosphorylation. These seminal observations pro-
vide insight into how n-3 PUFA may provide chemoprevention of
prostate cancer.
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Figure 7. DHA inhibits Bad phosphorylation through SDC-1. PC3 (A) and LNCaP (C) cells were treated with DHA (30 and 60 μM) or SDC-1
ectodomain (50, 100, and 150 nM) for 48 hours. Total proteins were used to measure p-Bad (S112) and total Bad by Western blot assay.
PC3 cells (B) and LNCaP cells (D) were transfected with control siRNA or SDC-1 siRNA for 6 hours and then supplemented with growth
medium containing 1% FBS for 24 hours. Cells were treated with DHA (60 μM) or SDC-1 ectodomain (150 nM) for 48 hours before harvest.
Total Bad and p-Bad (S112) were measured by Western blot assay. All data shown are representative of three independent experiments.
Relative ratios and SEM are shown in graphs, and values representing the mean ± SD (n= 3) with different letters are significantly different
(P < .05).
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